Natera, Inc. (NASDAQ:NTRA) Given Average Rating of “Moderate Buy” by Analysts

Shares of Natera, Inc. (NASDAQ:NTRA) have earned an average rating of “Moderate Buy” from the eighteen research firms that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $249.20.

A number of research analysts have issued reports on the company. TD Cowen restated a “buy” rating on shares of Natera in a research note on Wednesday, January 7th. Canaccord Genuity Group reissued a “buy” rating on shares of Natera in a report on Monday, January 12th. Guggenheim raised their price objective on shares of Natera from $230.00 to $270.00 and gave the stock a “buy” rating in a report on Monday, January 5th. Zacks Research raised shares of Natera from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 1st. Finally, Barclays increased their target price on shares of Natera from $230.00 to $270.00 and gave the company an “overweight” rating in a research report on Monday, December 15th.

Natera Stock Performance

Natera stock opened at $216.10 on Friday. The stock has a market cap of $29.89 billion, a PE ratio of -94.37 and a beta of 1.64. Natera has a fifty-two week low of $125.38 and a fifty-two week high of $256.36. The firm’s 50-day simple moving average is $227.00 and its 200 day simple moving average is $203.19.

Natera (NASDAQ:NTRA) last released its earnings results on Thursday, February 26th. The medical research company reported $0.35 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.81. The company had revenue of $665.50 million during the quarter, compared to analyst estimates of $600.68 million. Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.During the same period in the prior year, the company posted ($0.41) earnings per share. As a group, analysts predict that Natera will post -1.49 EPS for the current fiscal year.

Key Natera News

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Q4 earnings sharply beat expectations — Natera reported EPS of $0.35 versus consensus losses, and revenue of $665.5M, up 39.8% year‑over‑year, driven by product growth. This combination of an earnings surprise and strong top‑line growth is the main positive catalyst. Natera (NTRA) Tops Q4 Earnings and Revenue Estimates
• Positive Sentiment: Gross margins improved materially — the company reported a Q4 gross margin of ~66.9%, signaling better unit economics as volumes scale, which supports higher operating leverage going forward. Natera Reports Fourth Quarter and Full Year 2025 Financial Results
• Neutral Sentiment: FY‑2026 revenue guidance was provided in a range of ~$2.6B–$2.7B, roughly in line with Street expectations, giving investors more visibility on growth but not a material upside to consensus. Natera Reports Fourth Quarter and Full Year 2025 Financial Results
• Neutral Sentiment: Management hosted an earnings call and published a slide deck and transcript — useful for details on adoption trends, margin drivers, and FY‑2026 assumptions; transcripts and call notes are available for deeper review. Natera, Inc. (NTRA) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Company remains unprofitable on a net basis — despite the beat, Natera reported a negative net margin and negative return on equity, and its valuation metrics still reflect losses, which leaves upside dependent on sustaining margin expansion and converting revenues to net profits. Natera Q4 Earnings Snapshot / MarketBeat

Insider Buying and Selling at Natera

In other Natera news, CFO Michael Burkes Brophy sold 37,175 shares of the firm’s stock in a transaction on Wednesday, January 21st. The stock was sold at an average price of $242.54, for a total value of $9,016,424.50. Following the completion of the sale, the chief financial officer directly owned 64,123 shares of the company’s stock, valued at $15,552,392.42. This trade represents a 36.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Solomon Moshkevich sold 23,205 shares of the business’s stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $234.74, for a total value of $5,447,141.70. Following the completion of the sale, the insider owned 144,992 shares in the company, valued at approximately $34,035,422.08. The trade was a 13.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 368,119 shares of company stock valued at $85,956,782 in the last quarter. Insiders own 5.63% of the company’s stock.

Hedge Funds Weigh In On Natera

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Palladiem LLC bought a new position in Natera in the 4th quarter valued at $31,000. Horizon Investments LLC purchased a new stake in shares of Natera in the third quarter worth $32,000. Bank of Jackson Hole Trust raised its position in shares of Natera by 103.8% in the fourth quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company’s stock worth $37,000 after buying an additional 83 shares in the last quarter. Sound Income Strategies LLC boosted its stake in Natera by 95.7% during the third quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company’s stock valued at $39,000 after buying an additional 110 shares during the period. Finally, Kemnay Advisory Services Inc. purchased a new position in Natera during the fourth quarter worth about $39,000. Institutional investors own 99.90% of the company’s stock.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.